CalciMedica, Inc. (CALC)
Automate Your Wheel Strategy on CALC
With Tiblio's Option Bot, you can configure your own wheel strategy including CALC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CALC
- Rev/Share 0.0
- Book/Share 0.771
- PB 3.7742
- Debt/Equity 0.0
- CurrentRatio 5.6555
- ROIC -1.1946
- MktCap 40658520.0
- FreeCF/Share -2.325
- PFCF -1.2383
- PE -2.1775
- Debt/Assets 0.0
- DivYield 0
- ROE -1.5672
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif. , March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium …
Read More
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
Published: February 19, 2025 by: PRNewsWire
Sentiment: Neutral
LA JOLLA, Calif. , Feb. 19, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) being held March 3-6, 2025 in San Diego, CA.
Read More
About CalciMedica, Inc. (CALC)
- IPO Date 2023-06-14
- Website https://www.calcimedica.com
- Industry Biotechnology
- CEO A. Rachel Leheny
- Employees 14